Anti–tumor necrosis factor α therapy and heart failure: What have we learned and where do we go from here?

This publication has 59 references indexed in Scilit:

• IL-6, TNF-α and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort
  Atherosclerosis, 2003
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure
  Circulation, 2003
• How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH
  International Journal of Cardiology, 2002
• The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2002
• Tumor Necrosis Factor (TNF)–α–Induced Interleukin‐8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble Receptors
  The Journal of Infectious Diseases, 2000
• Wasting as independent risk factor for mortality in chronic heart failure
  Published by Elsevier ,1997
• Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.
  Journal of Clinical Investigation, 1996
• The mortality of rheumatoid arthritis
  Arthritis & Rheumatism, 1994
• Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide
  Science, 1992
• Detection and localization of tumor necrosis factor in human atheroma
  The American Journal of Cardiology, 1990